The kidney transplant recipient with hepatitis C infection: Pre- and posttransplantation treatment

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 3, 2007, Pages 563-575

  Terrault, Norah A ^a,b   Adey, Deborah B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

HEPATITIS C; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; RENAL REPLACEMENT THERAPY; REVIEW; VIROLOGY;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; RENAL DIALYSIS;

EID: 34748874598     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02930806     Document Type: Short Survey

References (126)

1. Fabrizi F, Bunnapradist S, Lunghi G, Aucella F, Martin P: Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence. Minerva Urol Nefrol 56: 249-257, 2004
2. Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ: Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 32: 629-634, 1998
3. Nakayama E, Akiba T, Marumo F, Sato C: Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 11: 1896-1902, 2000
4. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P: Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant 16: 1669-1674, 2001
5. Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS: Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 53: 1374-1381, 1998
6. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO: Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29: 257-263, 1999
7. Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr: Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis 37: 308-315, 2001
8. Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, Sanna R, van Der Heijden TG, van den Hoven H, van Hamersvelt HW, Quint W, van Doorn L-J: The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: A nationwide prospective study. J Infect Dis 182: 1291-1299, 2000
9. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36[Suppl 1]: S3-S20, 2002
10. Abbott KC, Bucci JR, Matsumoto CS, Swanson SJ, Agodoa LY, Holtzmuller KC, Cruess DF, Peters TG: Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 14: 2908-2918, 2003
11. United Network for Organ Sharing: The Organ Procurement and Transplantation Network. Transplants in the US by region. Updated: 2006. Available at: http://www.optn.org/latestData/rptData.asp. Accessed April 11, 2006
12. Lok AS, Ma OC, Chan TM, Lai CL, Chung HT, Ng CP, Lam JS: Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera. Hepatology 14: 756-762, 1991
13. Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Folsch UR, Schmidt WE: Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: A multicentre study in 2796 patients. Gut 51: 429-433, 2002
14. Dalekos GN, Boumba DS, Katopodis K, Zervou E, Sferopoulos G, Elisaf M, Tsianos EV, Siamopoulos KC: Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol Dial Transplant 13: 1804-1806, 1998
15. Schneeberger PM, Keur I, van der Vliet W, Van Hoek K, Boswijk H, van Loon AM, van Dijk WC, Kauffmann RH, Quint W, van Doom L-J: Hepatitis C virus infections in dialysis centers in The Netherlands: A national survey by serological and molecular methods. J Clin Microbiol 36: 1711-1715, 1998
16. Pawlotsky JM: Molecular diagnosis of viral hepatitis. Gastroenterology 122: 1554-1568, 2002
17. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S, Mousa M, Gitnick G: Acquisition of hepatitis C virus in hemodialysis patients: A prospective study by branched DNA signal amplification assay. Am J Kidney Dis 31: 647-654, 1998
18. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH: Progression of fibrosis in chronic hepatitis C. Gastroenterology 124: 97-104, 2003
19. Ustundag Y, Bilezikci B, Boyacioglu S, Kayatas M, Odemir N: The utility of AST/ALT ratio as a non-invasive demonstration of the degree of liver fibrosis in chronic HCV patients on long-term haemodialysis [Letter]. Nephrol Dial Transplant 15: 1716-1717, 2000
20. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, Han S, Wilkinson A, Lassman CR, Danovitch G: Histopathological features of hepatitis C in renal transplant candidates. Transplantation 69: 1479-1484, 2000
21. Sterling RK, Sanyal AJ, Luketic VA, Stravitz RT, King AL, Post AB, Mills AS, Contos MJ, Shiffman ML: Chronic hepatitis C infection in patients with end stage renal disease: Characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 94: 3576-3582, 1999
22. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36: 986-992, 2002
23. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526, 2003
24. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ: Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 127: 1704-1713, 2004
25. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 41: 935-942, 2004
26. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J: Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 38: 481-492, 2003
27. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbertbismuth F, Lebray P, Pol S: Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation 80: 1550-1555, 2005
28. Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo JM: Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 3: 357-360, 2003
29. Bruchfeld A, Wilczek H, Elinder CG: Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 78: 745-750, 2004
30. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA: The impact of hepatitis C virus viremia on renal graft and patient survival: A 9-year prospective study. Am J Kidney Dis 43: 131-139, 2004
31. Periera BJ, Wright TL, Schmid CH, Levey AS: The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 60: 799-805, 1995
32. Stehman-Breen CO, Psaty BM, Emerson S, Gretch D, Bronner M, Marsh C, Davis CL: Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 64: 281-286, 1997
33. Stempel CA, Lake J, Kuo G, Vincenti F: Hepatitis C: Its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 55: 273-276, 1993
34. Roth D, Zucker K, Cirocco R, DeMattos A, Burke GW, Nery J, Esquenazi V, Babischkin S, Miller J: The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 45: 238-244, 1994
35. Morales JM, Campistol JM: Transplantation in the patient with hepatitis C. J Am Soc Nephrol 11: 1343-1353, 2000
36. Izopet J, Rostaing L, Sandres K, Cisterne JM, Pasquier C, Rumeau JL, Duffaut M, Durand D, Puel J: Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 181: 852-858, 2000
37. Rostaing L, Izopet J, Cisterne JM, Arnaud C, Duffaut M, Rumeau JL, Puel J, Durand D: Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: Correlation with clinicopathological features. Transplantation 65: 930-936, 1998
38. Zylberberg H, Nalpas B, Carnot F, Skhiri H, Fontaine H, Legendre C, Kreis H, Brechot C, Pol S: Severe evolution of chronic hepatitis C in renal transplantation: A case control study. Nephrol Dial Transplant 17: 129-133, 2002
39. Kamar N, Rostaing L, Selves J, Sandres-Saune K, Alric L, Durand D, Izopet J: Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 5: 1704-1712, 2005
40. Alric L, Di-Martino V, Selves J, Cacoub P, Charlotte F, Reynaud D, Piette JC, Peron JM, Vinel JP, Durand D, Izopet J, Poynard T, Duffaut M, Rostaing L: Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 123: 1494-1499, 2002
41. di Belgiojoso GB, Ferrario F, Landriani N: Virus-related glomerular diseases: Histological and clinical aspects. J Nephrol 15: 469-479, 2002
42. Beddhu S, Bastacky S, Johnson JP: The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine (Baltimore) 81: 398-409, 2002
43. Cruzadc JM, Gil-Vernet S, Ercilla G, Seron D, Carrera M, Bas J, Torras J, Alsina J, Grinyo JM: Hepatitis C virus-associated membranoproliferative glomerulonephritis in renal allografts. J Am Soc Nephrol 7: 2469-2475, 1996
44. Cruzado JM, Carrera M, Torras J, Grinyo JM: Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 1: 171-178, 2001
45. Gallay BJ, Alpers CE, Davis CL, Schultz MF, Johnson RJ: Glomerulonephritis in renal allografts associated with hepatitis C infection: A possible relationship with transplant glomerulopathy in two cases. Am J Kidney Dis 26: 662-667, 1995
46. Hammoud H, Haem J, Laurent B, Alamartine E, Diab N, Defilippis JP, Berthoux P, Berthoux F: Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 11[Suppl 4]: 54-55, 1996
47. Roth D, Cirocco R, Zucker K, Ruiz P, Viciana A, Burke G, Carreno M, Esquenazi V, Miller J: De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 59: 1676-1682, 1995
48. Weiner SM, Thiel J, Berg T, Weber S, Krumme B, Peter HH, Rump LC, Grotz WH: Impact of in vivo complement activation and cryoglobulins on graft outcome of HCV-infected renal allograft recipients. Clin Transplant 18: 7-13, 2004
49. Rossi P, Bertani T, Baio P, Caldara R, Luliri P, Tengattini F, Bellavita P, Mazzucco G, Misiani R: Hepatitis C virus-related cryoglobulinemic glomerulonephritis: Long-term remission after antiviral therapy. Kidney Int 63: 2236-2241, 2003
50. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G: Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330: 751-756, 1994
51. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM: Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 59: 732-737, 2001
52. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178-185, 2003
53. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G: Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant 5: 2433-2440, 2005
54. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13: 1374-1380, 2002
55. Gurwitz JH, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J: Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154: 97-101, 1994
56. Heisel O, Heisel R, Balshaw R, Keown P: New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 4: 583-595, 2004
57. van Duijnhoven EM, Christiaans MH, Boots JM, Goossens VJ, Undre NA, van Hooff JP: A late episode of post-transplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus. Am J Kidney Dis 40: 195-201, 2002
58. Baid S, Tolkoff-Rubin N, Farrell ML, Delmonico F, Williams WW, Hayden D, Ko D, Cosimi AB, Pascual M: Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: Role of hepatitis C infection. Transplant Proc 34: 1771-1773, 2002
59. Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, Bhan A, Bald S, Cosimi AB, Pascual M, Chung RT: Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 77: 703-710, 2004
60. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K: Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840-848, 2004
61. Valenti L, Pulixi E, Fracanzani AL, Dongiovanni P, Maggioni M, Orsatti A, Giarmi C, Fargion S: TNFalpha genotype affects TNF-alpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 43: 944-950, 2005
62. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gončales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002
63. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965, 2001
64. Sabry AA, Sobh MA, Sheaashaa HA, Kudesia G, Wild G, Fox S, Wagner BE, Irving WL, Grabowska A, El-Nahas AM: Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy. Nephrol Dial Transplant 17: 1924-1930, 2002
65. Rostaing L, Chatelut E, Payen J-L, Izopet J, Thalamas C, Ton-That H, Pascal J-P, Durand D, Canal P: Pharmacokinetics of aIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 9: 2344-2348, 1998
66. Bunnapradist S, Fabrizi F, Vierling J, Martin R, Moudgil A, Kamil E, Jordan S: Hepatitis C therapy with long term remission after renal transplantation. Int J Artif Organs 25: 1189-1193, 2002
67. Gonzalez-Roncero F, Gentil MA, Valdivia MA, Algarra G, Pereira P, Toro J, Sayago M, Mateos J: Outcome of kidney transplant in chronic hepatitis C virus patients: Effect of pretransplantation interferon-alpha2b monotherapy. Transplant Proc 35: 1745-1747, 2003
68. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L: Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14: 2092-2098, 2003
69. Ozgur O, Boyacioglu S, Telatar H, Haberal M: Recombinant alpha-interferon in renal allograff recipients with chronic hepatitis C. Nephrol Dial Transplant 10: 2104-2106, 1995
70. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59: 1426-1431, 1995
71. Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchincloss H, Colvin RB, Delmonico FL, Cosimi AB, Pascual M: Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 3: 74-78, 2003
72. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D, Suc JM: Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol Dial Transplant 10[Suppl 6]: 93-96, 1995
73. Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 4[Suppl 10]: 72-82, 2004
74. Fabrizi F, Poordad FF, Martin P: Hepatitis C infection and the patient with end-stage renal disease. Hepatology 36: 3-10, 2002
75. Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, Rosen CB, Wiesner RH, Charlton M: Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: Lessons on tolerability and efficacy. Liver Transpl 8: 623-629, 2002
76. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, Cohard M, Reynes M, Chevallier M, Ducerf C, Baulieux J, Geffner M, Albrecht JK, Bismuth H, Trepo C: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 124: 642-650, 2003
77. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P: Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 18: 1071-1081, 2003
78. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr: Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 98: 1610-1615, 2003
79. Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, Isik IO: Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21: 575-580, 2006
80. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M: Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 20: 991-993, 2005
81. Russo MW, Ghalib R, Sigal S, Joshi V: Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21: 437-443, 2006
82. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, Brown RS, Belle SH, Hoofnagle JH, Kleiner DE, Howell CD: Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470-477, 2006
83. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR: Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 39: 1702-1708, 2004
84. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 350: 2265-2271, 2004; published erratum appears in N Engl J Med 351: 1268, 2004
85. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485-1492, 1998
86. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352: 1426-1432, 1998
87. Pegasys® (peginterferon alfa-2a) [Package insert], Nutley, NJ, Hoffmann-La Roche Inc., 2004
88. Peg-Intron® (peginterferon alfa-2b) [Package insert], Kenilworth, NJ, Schering Corp., 2001
89. Lamb MW, Marks IM, Wynohradnyk L, Modi MW, Preston RA, Pappas SC: Peginterferon alfa-2a (40KD) (Pegasys) can be administered safely in patients with end-stage renal disease [Abstract 326]. Hepatology 34[Suppl 1]: 190A, 2001
90. Rivera M, Gentil MA, Sayago M, Gonzalez RF, Trigo C, Algarra G, Pereira P, Valdivia MA, Aguilar J: Treatment of hepatitis C vires with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 37: 1424-1425, 2005
91. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL: Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol 63: 232-235, 2005
92. Copegus® (ribavirin) [Package insert], Nutley, NJ, Roche Laboratories Inc., 2005
93. Tan AC, Brouwer JT, Glue P, van LR, Kauffmann RH, Schalm SW, de Vries RA, Vroom B: Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol Dial Transplant 16: 193-195, 2001
94. Bruchfeld A, Stahle L, Andersson J, Schvarcz R: Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C [Letter]. Nephrol Dial Transplant 16: 1729, 2001
95. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA: Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 36: 1831-1834, 2004
96. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL, Bowers PJ: Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 126: 1302-1311, 2004
97. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS: Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 98: 2491-2499, 2003
98. Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, Boeschoten EW, Krediet RT, Daha MR, Dekker FW: Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 68: 1215-1222, 2005
99. Harihara Y, Kurooka Y, Yanagisawa T, Kuzuhara K, Otsubo O, Kumada H: Interferon therapy in renal allograft recipients with chronic hepatitis C. Transplant Proc 26: 2075, 1994
100. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP: Interferon-alpha-induced acute renal allograft rejection. Transplantation 59: 1068-1070, 1995
101. Therret E, Pol S, Legendre C, Gagnadoux MF, Cavalcanti R, Kreis H: Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 58: 625-628, 1994
102. Shu KH, Lan JL, Wu MJ, Cheng CH, Chen CH, Lee WC, Chang HR, Lian JD: Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. Transplantation 77: 1894-1896, 2004
103. Tang S, Cheng IK, Leung VK, Kuok UI, Tang AW, Wing HY, Neng LK, Mao CT: Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 39: 875-878, 2003
104. Durlik M, Gaciong Z, Rowinska D, Rancewicz Z, Lewandowska D, Kozlowska B, Wyzgal J, Soluch L, Walewska-Zielecka B, Rowinski W, Lao M: Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipient: Transpl Int 11[Suppl 1]: S135-S139, 1998
105. Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhar AK, Cosimi AB: Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: Response to interferon-alpha therapy. Transplantation 66: 1254-1258, 1998
106. Ozdemir BH, Ozdemir FN, Sezer S, Colak T, Haberal M: De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 38: 492-495, 2006
107. Morales JM: Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc 36: 760-762, 2004
108. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M: Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 70: 255-261, 2000
109. Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W: Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1: 989-990, 1984
110. Kovarik J, Mayer G, Pohanka E, Schwarz M, Traindl O, Graf H, Smolen J: Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients. Cytomegalovirus infection prophylaxis leading to an increased incidence of irreversible rejections. Transplantation 45: 402-405, 1988
111. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D: Acute renal failure: in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74: 512-516, 1996
112. Luciani G, Bossola M, Muscaritoli M, Panocchia N, Ferrante A, Nanni G, Piccioni E, Tazza L, Grillo RL, Rossi FF, Castagneto M: Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C. J Nephrol 16: 417-420, 2003
113. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L: Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: Effects on renal function and liver histology. Am J Kidney Dis 42: 184-192, 2003
114. Cattral MS, Hemming AW, Wanless IR, Al Ashgar H, Krajden M, Lilly L, Greig PD, Levy GA: Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 67: 1277-1280, 1999
115. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH: Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123: 897-903, 1995
116. Quadri R, Giostra E, Roskams T, Pawlotsky JM, Mentha G, Rubbia-Brandt L, Perrin L, Hadengue A, Negro F: Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 73: 373-378, 2002
117. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, Lebray P, Sobesky R, Serpaggi J, Kreis H, Pol S: Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 78: 853-857, 2004
118. Garnier JL, Chevallier P, Dubernard JM, Trepo C, Touraine JL, Chossegros P: Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc 29: 783, 1997
119. D'Amico G: Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis. Kidney Int 54: 650-671, 1998
120. Kamar N, Rostaing L, Alric L: Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 69: 436-439, 2006
121. Baid S, Pascual M, Williams WW Jr, Tolkoff-Rubin N, Johnson SM, Collins B, Chung RT, Delmonico FL, Cosimi AB, Colvin RB: Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 10: 146-153, 1999
122. Morales JM, Campistol JM, Andres A, Rodicio JL: Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 6: 511-515, 1997
123. Stehman-Breen C, Alpers CE, Fleet WP, Johnson RJ: Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 81: 37-40, 1999
124. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P: Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 43: 617-623, 2004
125. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R: Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 13: 316-321, 2006
126. Benhamou Y, Pockros P, Rodriguez-Torres M, Gordon S, Shiffman M, Lurie Y, Afdhal N, Lamon K, Kim Y, Murphy B: The safety and efficacy of viramidine plus PegIFN alfa-2b versus ribavirin plus PegIFN alfa-2b in therapy-naïve patients infected with HCV: Phase 3 results (VISER1). J Hepatol 44[Suppl 2]: S273, 2006